The present invention is related to methods of making crustacean oil compositions. In particular, the crustacean oil compositions are krill oil compositions. In some embodiments, the krill oil compositions are concentrated in phospholipids. These concentrated phospholipid krill oil compositions have a sufficient flowability to permit successful encapsulation at phospholipid concentrations that is currently unattainable in the art. Such phospholipid krill oil compositions are capable of encapsulation even though they may have a phospholipid concentration ranging between approximately 60%-99% and a viscosity ranging between 100,000-3,000,000 cP. Such concentrated phospholipid krill oil compositions may be created using a small molecule organic solvent/water extraction mixture and/or sub-critical or super-critical fluid extraction at low temperatures followed by a drying process to remove water and organic solvent (e.g., for example, ethanol).

The present invention relates to a nutritional product comprising a biological material derived from eggs and/or nauplii of stage I of a barnacle and its uses. The invention, especially discloses a feed for early live stages of aquatic animals such as fish or crustaceans comprising isolated eggs and/or nauplii of stage I of a barnacle or a material derived thereof. Methods for harvesting, isolating and preservation of the biological barnacle material are also disclosed.

The present invention relates to a nutritional product comprising a biological material derived from eggs and/or nauplii of stage I of a barnacle and its uses. The invention, especially discloses a feed for early live stages of aquatic animals such as fish or crustaceans comprising isolated eggs and/or nauplii of stage I of a barnacle or a material derived thereof. Methods for harvesting, isolating and preservation of the biological barnacle material are also disclosed.

To provide an ether-type glycerophospholipid-containing composition that has excellent heat stability and also has oxidation stability and storage stability. An ether-type glycerophospholipid-containing composition that comprises not more than 20 mass % of an ether-type glycerophospholipid and not less than 80 mass % of a cyclodextrin. Owing to this constitution, the ether-type glycerophospholipid is clathrated in the cyclodextrin. Thus, the ether-type glycerophospholipid-containing composition has highly excellent heat stability as well as temporal stability such as oxidation stability and storage stability even in a powdery form.

Provided is a solid beverage for conditioning yin deficiency constitution. The solid beverage includes the following components in parts by weight: 30-55 parts of smoked plum, 29-51 parts of lilium brownii, 27-50 parts of polygonatum odoratum, 30-52 parts of mulberry leaves, 27-48 parts of mulberries, 26-58 parts of fresh reed rhizome, 67-94 parts of oysters, 3-15 parts of amomum villosum, 27-50 parts of dextrin, 16-43 parts of maltodextrin, 38-70 parts of soluble starch and 0.15-0.35 parts of aspartame. The solid beverage is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, a long-term consumption of the solid beverage has certain effects on the improvement of yin deficiency constitution, and the production process thereof is suitable for industrial mass production.

Provided is a solid beverage for conditioning yin deficiency constitution. The solid beverage includes the following components in parts by weight: 30-55 parts of smoked plum, 29-51 parts of lilium brownii, 27-50 parts of polygonatum odoratum, 30-52 parts of mulberry leaves, 27-48 parts of mulberries, 26-58 parts of fresh reed rhizome, 67-94 parts of oysters, 3-15 parts of amomum villosum, 27-50 parts of dextrin, 16-43 parts of maltodextrin, 38-70 parts of soluble starch and 0.15-0.35 parts of aspartame. The solid beverage is simple and convenient to prepare, the raw materials used are all medicinal materials with dual-purpose of drug and food, and the auxiliary materials used also meet the national standard GB2760-2011 (the National Food Safety Standard for Food Additive Use). Thus, the solid beverage is safe to consume and good in taste, a long-term consumption of the solid beverage has certain effects on the improvement of yin deficiency constitution, and the production process thereof is suitable for industrial mass production.

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO.sub.2 or CO.sub.2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO.sub.2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO.sub.2 or CO.sub.2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO.sub.2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

The present invention relates to compositions comprising phospholipids for delivery of bioactive compounds such as ethyl esters, fish oil concentrates, cannabinoids, CoQ10 and curcumin under conditions such the bioavailability of the bioactive compounds is enhanced.

The present invention relates to compositions comprising phospholipids for delivery of bioactive compounds such as ethyl esters, fish oil concentrates, cannabinoids, CoQ10 and curcumin under conditions such the bioavailability of the bioactive compounds is enhanced.